《新股消息》鷹瞳科技(02251.HK)今日起招股 入場費8,211.93元
生物科技公司鷹瞳科技(02251.HK),擬於全球發行2,226.72萬股H股,其中10%於本港公開發售,每股招股價介乎75.1元至至81.3元,每手100股,入場費8,211.93元。今日起招股,至周五(29日)截止,預期同日定價,11月5日上市。
公司為中國首批提供人工智能視網膜影像識別無創、快速、有效且可擴展的早期檢測、診斷及健康風險評估解決方案的公司之一,其的核心產品Airdoc-AIFUNDUS為一款人工智能醫療器械軟件,獲批用於輔助診斷糖尿病視網膜病變,以協助醫生做醫療診斷,為同類產品中首個獲得中國藥監局第三類醫療器械證書的醫療器械。
是次上市聯席保薦人、聯席代表、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人為瑞銀集團及中信證券,聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人為招銀國際、安信國際及海通國際,聯席賬簿管理人及聯席牽頭經辦人為平證證券、復星恆利、廣發證券、國都香港及浦銀國際。
公司引入基石投資者,合共投資6,850萬美元,其中CloudAlpha投資1,500萬美元,廣發基金、LAV及WT分別投資1,000萬美元,LMR投資750萬美元,常春藤投資700萬美元,Lake Bleu Prime及OrbiMed分別投資50萬美元。
以招股價中位數78.2元計,公司料集資所得淨額16.33億元,其中50%用於其核心產品Airdoc- AIFUNDUS的持續優化、開發及商業化,19%用於於資助硬件設備的研發及生產,10%用於資助正在進行的及未來的健康風險評估解決方案的研發,6%用於產品組合的開發,5%用於學術及研究機構就聯合研究項目進行的合作提供資金,其餘10%用於營運資金及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.